breast positioning News
-
Showcase
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. Because of liver enzyme elevations ...
-
Koning Selected as Finalist to Present at Women’s Health Innovation Summit
Boston, MA: Koning has been selected as a finalist to present at the Women’s Health Innovation Summit on September 14, 2021. Of over 100 applicants, Koning is one of only ten companies that has been chosen and will showcase the Koning Breast CT - a technology that will change millions of women’s lives around the world through no compression, low dose, and true 3D imaging. ...
-
RxPONDER Study Results Demonstrate that the Oncotype DX Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negative disease Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive ...
-
Transpara breast AI reduces false positives and radiologists` workload in largest Danish screening programme
The team running the country's largest breast screening programme have shown that using Transpara breast AI further confirmed the enormous contribution of this technology to breast cancer detection: not only to reduce the number of false positives but also to reduce radiologists' workload by over 60%. In Copenhagen, the biannual breast screening programme for women aged from 50 to 69, has been ...
-
Exposure to Organic Solvents Before First Childbirth May Increase Hormone-related Breast Cancer Risk
Among women with a family history of breast cancer, those who worked with organic solvents prior to their first full-term birth had an increased risk for hormone receptor-positive breast cancer, according to data published in Cancer Research, a journal of the American Association for Cancer Research. “The time between puberty and before first birth is an important period of development ...
-
Exposure to Organic Solvents Before First Childbirth May Increase Hormone-related Breast Cancer Risk
Among women with a family history of breast cancer, those who worked with organic solvents prior to their first full-term birth had an increased risk for hormone receptor-positive breast cancer, according to data published in Cancer Research, a journal of the American Association for Cancer Research. “The time between puberty and before first birth is an important period of development ...
-
Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer
Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion diagnostic (CDx) that will utilize Thermo Fisher's next-generation sequencing (NGS)-based Oncomine Dx Target Test. The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be ...
-
New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score Test to Inform Clinical Decision-making
Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium (SABCS) supporting the clinical value of the ...
-
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test
RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women Results have already led to updated NCCN Guidelines® for breast cancer New RxPONDER results to be featured in oral presentation at 2021 San Antonio Breast Cancer Symposium (SABCS) Exact Sciences ...
-
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: Phase III clinical trial, Flamingo-01, has officially started Multiple sites have begun the screening ...
-
New phase of breast cancer treatment trial provides fresh hope for patients with incurable disease
Patients with incurable breast cancer could potentially benefit from new Welsh-led research, latest evidence suggests. The research, carried out by Velindre University NHS Trust, in partnership with AstraZeneca and Cardiff University over 10 years was presented at the world renowned American Society of Clinical Oncology conference on 4 June in Chicago and published simultaneously in the ...
By MediWales
-
Beyond Cancer Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announces entry into a sponsored research agreement with Stanford School of Medicine and the appointment of Frederick M. Dirbas, MD, Associate Professor of Surgery, Division of Surgical Oncology, Stanford School of Medicine ...
-
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery
SAN DIEGO, CA – Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging, today announced that the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery. Pegloprastide is designed ...
-
New Oncotype DX Real-World Evidence Shows for the First Time the Practice-Changing Impact of TAILORx Results
Data obtained in real-life setting from more than 800 patients with node-negative or nodepositive early-stage breast cancer highlight the test’s impact on clinical practice with chemotherapy-sparing effect Publication of landmark TAILORx study results led to greater reduction in chemotherapy recommendations Exact Sciences Corp. today announced results from a prospective clinical ...
-
Multiple Publications and Presentations Underscore Seno Medical’s Value Proposition in Mitigating the Cost and Burden of Unnecessary Breast Biopsies
Seno Medical Instruments, Inc. (Seno Medical), the leader in new technology for breast cancer diagnosis using opto-acoustic ultrasound (OA/US) imaging to differentiate benign from malignant masses, today provided a summary of key 2018 data publications and presentations that demonstrate the clinical utility and healthcare economic benefits of its proprietary, cutting-edge technology. ...
-
Women’s Health and AI, CureMetrix Joins Forces with AuntMinnie.com and AuntMinnieEurope.com for Virtual Conference
CureMetrix, Inc., a global healthcare technology company that delivers AI-driven software for radiology once again joins forces with AuntMinnie and AuntMinnieEurope, along with industry experts, for the AuntMinnie.com 2022 Virtual Conference - AI, Women’s Health, and More - to be held on March 30 and 31, 2022. Women want to know that the latest technology is supporting their healthcare ...
-
Showcase
Primary Results of Onawa (Solti-1802) Trial: A Window Of Opportunity Trial Of Onapristone In Postmenopausal Women With Progesterone Receptor-Positive/Her2-Negative Early Breast Cancer
PGR is an estrogen-responsive gene and progesterone receptor (PR) expression, evaluated by immunohistochemistry (IHC), is used as a clinical biomarker of estrogen signaling and estrogen receptor (ER) functionality.1 Despite the well-studied role of PGR as mitogen and independent ER activator, anti-progestins for the treatment of BC have been poorly tested. While limited success for ...
-
Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant’s PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...
-
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer
Exact Sciences today announced that its Oncotype DX Breast Recurrence Score test has been recognised as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes, including micro metastases, by the National Comprehensive Cancer Network (NCCN)ii in its updated guidelines for breast cancer. iii The Oncotype DX ...
-
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in Node-Positive Early-Stage Breast Cancer
Improved quality of care and significant cost savings using the test to guide adjuvant chemotherapy treatment Analysis based on first results from the independent RxPONDER study which identified the majority of women with one to three positive nodes who receive no benefit from chemotherapy Exact Sciences today announced results from a health economic analysis of the Oncotype DX Breast ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you